PofoliaShared via Pofolia

Journal of Ect· 2026Q2

Two-Year Clinical Outcomes of Vagus Nerve Stimulation for Higher-Grade Treatment-Resistant Depression

Kfir Feffer, Ido Straus, Zeev Feldman, Aviv Solomon et al.

Short summary

Vagus nerve stimulation (VNS) reduced depressive severity by 48% and achieved a clinical response in 87.5% of patients with higher-grade treatment-resistant depression (HG-TRD) over 24 months.

AI-generated from the title and abstract; the full text is not read.

Key points

  • VNS led to a 48% mean reduction in MADRS scores over 24 months in patients with HG-TRD.
  • 87.5% of participants experienced a clinically defined response to VNS during the 24-month follow-up.
  • Suicidality scores (MADRS item-10) significantly decreased and remained improved throughout the study.
  • VNS demonstrated high tolerability and long-term adherence with no serious safety concerns identified.

AI-generated from the title and abstract; the full text is not read.

Abstract

Objectives: To assess 24-month clinical outcomes of vagus nerve stimulation (VNS) in individuals with higher-grade treatment-resistant depression (HG-TRD) treated within a national open-label program, focusing on depressive severity, suicidality, safety, tolerability, and rates of response and remission. Methods: A prospective, open-label, multicenter cohort study was conducted on 19 patients who underwent VNS implantation between 2020 and 2023. Clinical assessments were performed at baseline and at 6, 12, 18, and 24 months. Depressive symptoms were evaluated using the Montgomery-Åsberg Depression Rating Scale (MADRS), including item 10 for suicidality. Outcomes included mean percentage change in MADRS scores, rates of response, remission, partial response, adverse events, and adherence. Sixteen participants completed the 24-month follow-up. All analyses were exploratory. Results: MADRS scores decreased significantly by 6 months ( P <0.001) and remained improved throughout follow-up, with a mean reduction of 48% in 24 months. Cumulatively, 87.5% of participants experienced a clinically defined response during the 24-month period. Suicidality (MADRS item-10 scores) decreased significantly ( P <0.001) and this improvement persisted throughout follow-up. No serious safety concerns were identified. Tolerability and long-term adherence were high, with most patients continuing active device use throughout the study period. Conclusions: In this open-label, multicenter cohort of individuals with HG-TRD, VNS was associated with substantial and durable reductions in depressive severity and suicidality over 24 months. Despite limitations related to sample size and lack of a control group, the magnitude and persistence of clinical benefit support VNS as a viable long-term treatment for carefully selected patients with severe, highly resistant depression.

The authors' abstract, as published at the source. Journal of Ect, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Get it on Google Play Download on the App Store

Related papers

Field: Neurology (Neuroscience)

NeurologyNeuroscience